Shuttle Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharmaceuticals Holdings, Inc. announced that the first three patients in its Phase II clinical trial of Ropidoxuridine for the treatment of patients with glioblastoma have been successfully dosed.